Business
Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia
Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer Ingelheim has informed the Company of its decision not to exercise its exclusive option to license Nxera’s GPR52 agonist program for schizophrenia, including the Phase 2 ready lead compound NXE0048149 (“NXE’149”). No further information was provided by Boehringer Ingelheim. All rights to the GPR52 portfolio will revert in full to Nxera Pharma together with a
About this update from Nxera Pharma Co., Ltd.
[{"type":"image","alt":"Nxera Pharma","displaySize":"","headline":null,"caption":"Nxera Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MMtO8FGLy1ULu25TBGkF3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3c5c5d1f11d2ca9444665ce7b9191638","width":300,"height":101}},"lazy":false},{"type":"text","content":"Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer Ingelheim has informed the Company of its decision not to exercise its exclusive option to license Nxera’s GPR52 agonist program for schizophrenia, including the Phase 2 ready lead compound NXE0048149 (“NXE’149”). No further information was provided by Boehringer Ingelheim. All rights to the GPR52 portfolio will revert in full to Nxera Pharma together with all data and intellectual property generated under the collaboration in accordance with the terms of the Collaboration and License Option Agreement.","length":647,"tagName":"p"},{"type":"text","content":"NXE’149 and other GPR52 agonists within the portfolio were designed by Nxera using its world-leading NxWave™ structure-based drug design platform to improve patient outcomes by simultaneously addressing positive, negative, and cognitive symptoms of schizophrenia.","length":263,"tagName":"p"},{"type":"text","content":"A Phase 1 trial evaluating single and multiple ascending doses of NXE’149 demonstrated a highly favourable safety profile, with NXE’149 well tolerated in healthy participants across all dose levels. There were no severe or serious adverse events (AEs) and no AEs leading to discontinuation. Pharmacokinetic analyses showed dose-proportional exposure, equivalent free concentrations in plasma and cerebrospinal fluid at steady state, and a long half-life supporting once-daily dosing. Notably, pharmacodynamic endpoints including cognitive assessments, neurophysiological measures and peripheral biomarkers provided evidence of engagement of brain circuitry relevant to the treatment of schizophrenia and related disorders.","length":722,"tagName":"p"},{"type":"text","content":"The expression of GPR52 in brain regions associated wi...